A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Alopecia Areata

Part of paid clinical trials in Santa Monica, California.

Sponsor
Bristol-Myers Squibb
Study ID
NCT05556265
Phase
PHASE2
Status
Terminated

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Not accepted

Interventions

  • Deucravacitinib — DRUG
    Specified dose on specified days
  • Placebo — OTHER
    Placebo was administered.

Study Details

The purpose of this study is to evaluate the efficacy of deucravacitinib versus placebo at Week 24 and safety and tolerability of deucravacitinib versus placebo in adults with alopecia areata.

Key Dates

Start date
Nov 8, 2022
Status verified
May 2025
Primary completion
Jan 6, 2024
Completion
May 16, 2024

Study Design

Enrollment
94 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Deucravacitinib Dose 1
  • Experimental: Deucravacitinib Dose 2
  • Placebo Comparator: Placebo, followed by Deucravacitinib Dose 1 or Dose 2.

Primary Outcome Measure

Change From Baseline in Severity of Alopecia Tool Score at Week 24 in Placebo-Controlled Treatment Period [ Time Frame: Baseline (Day 1) and Week 24 ]

Locations (12)

FacilityCityStateZIPSite coordinators
Local Institution - 0016Santa MonicaCalifornia90404-2120-
Local Institution - 0036New HavenConnecticut06510-
Local Institution - 0018TampaFlorida33624-2038-
Local Institution - 0023Clinton TownshipMichigan48038-1137-
Local Institution - 0024New YorkNew York10029-6501-
Local Institution - 0019Chapel HillNorth Carolina27516-4061-
Local Institution - 0011PortlandOregon97201-5134-
Local Institution - 0032PittsburghPennsylvania15213-3403-
Local Institution - 0012AustinTexas78759-
Local Institution - 0013HoustonTexas77004-8098-
Local Institution - 0014San AntonioTexas78213-2250-
Local Institution - 0017South JordanUtah84095-

Related coverage on Hipa.ai

Find similar trials in Santa Monica, CA

Related Studies